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Summary
A vaiiant in prothrombm (clottmg factor II), a G to A tiansition at
nucleotide position 20210, has lecently been shown to be associated
with the prothiombm plasraa levels and the nsk of both venous and
artenal throrabosis The purpose of this study was to mvestigate the
prevalence of caniership of this mutation in vanous populations
We combmed data fiom 11 centres m nme countnes, where tests
foi this mutation had been performed m groups representmg the
general population We calculated an oveiall pievalence estimate, by a
piecision weighted method, and, smce the distnbution of the preva-
lences did not appear homogeneous, by an unweighled average of
the prevalences We exarmned differences in the prevalences by
geographical location and ethnic background äs a possible explanation
for the heterogeneity
Among a total of 5527 mdividuals who had been tested, 111 hetero-
zygous camers of the 2021OA mutation were found The prevalence
estimates vaned from 07 to 40 between the centres The overall
prevalence estimate was 2 0 peicent (CI95 l 4-2 6%) The Variation
around the summary estimate appeared more than was expected by
chance alone, and this heteiogeneity could be explamed by geographic
differences In southern Euiope, the prevalence was 3 0 percent (0195
2 3 to 3 7%), neaily twice äs high äs the prevalence m northern Euiope
(l 7%, CI95 l 3 to 2 2%) The piothrombm vanant appeared very rare
m mdividuals fiom Asian and Afncan descent
The 20210A prothiombm vaiiant is a common abnormality, with a
prevalence of carnership between one and four percent It is more
common m southern than m northern Europe Smce this distnbution
withm Europe is very diffeient to that of anothei prothrombotic muta
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tion (factor V Leiden or factor V R506Q), foundei effects are the most
likely explanation for the geographical disttibution of both mutations
Introduction
Recently, we leported a mutation m clottmg factor II (prothrombm)
that was associated with plasma levels of prothrombm and with the nsk
of deep-vem thiombosis [1] The smgle base Substitution (G to A) at
position 20210 [2] of the 3' untranslated legion of the prothrombm
gene was found in 18 percent of probands of thrombophilic famihes, six
peicent of unselected consecutive patients with deep-vem thrombosis
and 2 percent of healthy controls [1] Thus, carnership of this mutation
led to a three-fold mcreased nsk of venous thrombosis [1]
The mutation also affects the nsk of artenal disease among young
women we found a four fold mcreased nsk of myocardial mfarction
among camers of the factor II20210A allele [3], while among men the
nsk was mcreased l 5-fold [4]
Several recent reports, mamly m the foim of meetmg abstracts and
piesentations, have addiessed the venous and artenal nsk mciease m
other populations [5-11] One of the pioblems with the studies is that
the relatively low prevalence of the mutation m the general population
leads to large uncertamties m the usk estimates Moreover, it is
possible that the pievalence depends on ethmcity and geography, äs
was found for the factor V Leiden mutation
Therefore, we decided to combme our data on the frequency of the
factoi II 20210A vanant m the general population, first, to arnve at a
summaiy allele frequency estimate, and secondly, to examme whether
there is heterogeneity in its distnbution
Methods
At the 11 centres from nme different countnes, testmg was performed
for prothiombm 20210 G to A carneiship in healthy mdividuals The ongin of
each study group is hsted m Table l Most centres were in Euiope and the
Middle East, and ranged fiom Scandmavia to the Mediterranean In addition,
we mcluded a study from South-Amenca (Campinas, Brazil) and from North
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Table l Numbers and ongm of the tested mdividuals per centre
centre ongin of tested mdividuals
Europe/Middle Hast.

















medical Controls (n=646 n-291)1 population Controls
(n=474) blood donors (n-249) Hospital statf(n 100)
population controls1
Hospital staff (n 272) population controls (n-13 8)
medical controls3
blood donors (n~l 16) medical controls (n=166)4
population controls (n=l 11) newborns (n=102)
population controls
blood donors
blood donors (n-96) population controls (n~54)
America
Brazil[18] 522 population controls (n=83) newborns (n-295) hospital staff
(n=144)!
United States [3] 384 population controls
' orthopedic surgery patients (n-646) rheumatoid arthntis patients (n~29l)
2 from vanous ethmc groups Ashkenazi North African Middle Eastern (Iraqi and Iraman)
Yememte and Ethiopian Jews and Arabs
3 medical checkup centre visitors excludtng those with cardiovascular disease
4 mdividuals who underwent orthopedic surgery (n~142) or gave blood samples for vanous
reasons (n-24) excluding those with a history of cardiovascular disease
5 from three regions with different ethmc background Amazoman Indians (n~83) Caucasians
(n=295 Campinas south-east) and with a mainly African descent (n-144 Bahia north
east)
America (Seattle, United States) These latter two centres and the Tel Aviv
center also mcluded non-whites, while all other solely or mamly compnsed
Caucasian mdividuals
The selection of mdividuals vaned between the vanous studies In most
cases, an effort was made to include healthy mdividuals, äs a sample from the
population These samples ranged from hospital employees, to blood donors,
newborns, and vanous groups of mdividuals visitmg health care providers
('medical control groups') and, fmally formal control groups from the general
population (Table 1) In none of the centres, mdividuals were selected m a way
that would lead to preferential mclusion of mdividuals with thrombotic disease,
while m most centres those with a history of cardiovascular disease were







Br US Mo Ma Sri Am Le Pa Vi Fe TA All
Fig l Prevalence of carnership (m percentage pomts) of prothrombm
2021OA, per centre, m geographical order America US = United States
(Seattle), Br = Brazil, northern Europe Mo = Malmo, Ma = Manchester,
Sh = Sheffield, Am = Amsterdam, Le = Leiden, southern Europe/Middle-East
Pa = Paris, Vi = Vienna, Fe = Ferrara, T A = Tel Aviv The European centres
are m order of decreasmg latitude On the nght (All) the overall summary
estimate is given (straight average) All estimates are shown with a 95%
confidence mterval
All centres except one used a strategy for the detection of the 20210 A
allele similar to the one from the original report [1] Leiden, Campinas,
Amsterdam, Seattle Malmo, Vienna, and Manchestei used amphfication
primers exactly äs descnbed before [1] Tel-Aviv, Paris, and Sheffield used
primers that differ from the Originals but that still use the concept of mtroducmg
a Hmd III recogmtion site with a mutagemc primer The sequences of these
primers and the reaction conditions can be obtamed from the respective authois
Each centre reported that their local protocol was robust, which mdicates that
pnmer choice is not cntical m the assay for the prothrombm mutation Ferrara
used allele specific amphfication (ASA) to discnmmate the prothrombm
alleles Two allele specific primers, 5'-CTGGGAGCATTGAAGCTC 3'
(nucleotides 20227-20210) and 5' CTGGGAGCATTGAAGCTT 3' (nucleo
tides 20227-20210) were used äs reverse primers m combmation with the
forward primer 5'GGGAAATATGGCTTCTACA-3' (nucleotides ^20035-
20054) The presence of an additional mismatch m the ASA primers mcreased
selectivity of the ASA
We categonzed the prevalence of carners of the prothrombm 20210
A allele per centre, and pooled the estimates by two methods first, by calculat-
mg an average weighted for the number of carriers per centre This average
gives most weight to the more precise estimates, smce the vanance, under
Poisson assumptions, depends on the numbei of carneis This is the
appropnate method when it is assumed that the 'true' allehc prevalence is the
same m all study groups, and that all observed Variation m prevalences is
random This precision-weighted average is not the appropnate appioach when
the allehc prevalences are not constant We assessed homogeneity of the
prevalences by Poisson modelmg of the prevalence rates and comparmg the
model with only the constant, to the saturated model with a dummy vanable for
centre, with the hkelihood ratio statistic As a second approach we calculated an
unweighted average of the prevalence estimates (le, the aveiage with equal
weights, which is the straight mean of the prevalence estimates) This
unweighted straight average is more appropnate when homogeneity cannot be
assumed Prompted by the reports on a north south differencc m the prevalence
of another common prothrombotic mutation, factor V Leiden [ 12], wc stratifled
the analysis by geogiaphy mto northern and southern European countnes
(the latter mcludmg the Middle East)
Foi an analysis by ethmcity, we grouped togethei African Amcncans fiom
the United States and Brazil, and Ethiopian Jews from Israel äs mdividuals with
an Afncan descent Native-Amencans, le, American Indians fiom north
western United States and the Amazon region m Brazil, were grouped together
äs mdividuals with an Asian background
Confidence mtervals for mdwidual prevalence estimates were based on
exact Poisson hmits [13] and for pooled estimates on the normal approxima
tion of the Poisson distribution
Results
In the 11 cenlres, a total of 5527 mdividuals were tested The total
number of mdividuals per centre vaned from 150 to 1760 Among
these 5527 mdividuals, 1 1 1 heterozygous carners of prothrombm
20210A were identified No homozygous mdividuals were found The
number of camers vaned from l to 33 per centre, and the prevalence of
carnership ranged from 0 7 percent to 4 0 percent (Fig l)
The overall prevalence was 2 3 peicent (CI95 l 9 to 2 6%), when a
weighted average was calculated The vanation of the prevalence
estimates appeared to be more than would be expected by random
Variation around one underlymg mean (LRS = 16 9, p = 0 08) There
fore, we calculated the average with equal weights, this straight average
of prevalences was 2 0 percent (CI95 l 4 to 2 6%)
There was a clear relationship of the prevalence with the geographic
latitude m Europe (mcludmg Israel) in the centres north of 50° N
(Malmo, Manchester, Sheffield, Amsterdam, Leiden) there were 45
carriers among 2756 mdividuals tested, yieldmg a precision-weighted
prevalence of l 7 percent (CI95 l 3 to 2 2%), m the centres located
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south of 50°N (Paris, Vienna, Ferrara, Tel Aviv) we found 55 carriers
among a total of 1868, yielding a prevalence of 3.0 percent (CI95 2.3 to
3.7%). So, the prevalence of the prothrombm vanant was nearly twice
äs common in the southern äs in the northern regions (χ2 = 9.05, df = l,
p = 0.003). As can be seen in the figure, where the centres are shown in
geographical order, in each of the four centres south of 50° N the
prevalence estimate was higher than in each of the five centies north
of50°N.
Three centres included non-Caucasians: Brazil, Seattle and
Tel-Aviv, which allowed a separate analysis of individuals with a
different ethnic background. Among individuals with an African
background, 2 carriers of factor II 2021OA were found among 300
individuals (0/9 m Seattle, 2/144 in Bahia, Brazil, and 0/147 among
Ethiopian Jews in Israel). Taken together, this accounts for a prev-
alence of carriership of only 0.67 percent (CI95: 0.08 to 2.4%,
comparison with Caucasians χ2 =3.02, p = 0.08 ). Among 103 Native
Americans, ie, individuals with an Asian background (20 from Seattle,
83 from the Amazon region in Brazil) no carrier was detected
(prevalence CI95: 0 to 3.6%, comparison with Caucasians χ2 =2.24,
p = 0.13).
Discussion
We have combined the data on the prevalence of carriership of the
prothrombin 20210A variant fiom 11 centres, including a total of 5527
healthy individuals among whom 111 carried the vanant. The estimate
of the overall prevalence, under the assumption of homogeneity, was
2.3 percent (CI95 1.9 to 2.6%). The stiaight average of the prevalences
was 2 percent (0195 1.4-2.6%). We did not find any homozygous
individuals This is not surprising, since with an allele frequency of
l percent, we would expect homozygotes to occur in only l in 10,000.
The assumption of homogeneity did not appear true. Withm Europe,
there was an association with geographical location, with highei
prevalences in the southern than in the northern countnes. In southem
Europe/Middle Hast, the prevalence was 3 0 percent (CBS 2.3 to
3.7%), and m northern Europe it was 1.7 peicent (CI95 1.2 to 2.2%).
This distribution m Europe is different to that reported for factor V
Leiden, which has a high prevalence in northern Europe, especially
in southern Sweden, and a low prevalence in Italy [12]. It has been
hypothesized that such geographical differences might be the result
of geographical differences in other risk factors, and thus by differences
in genetic fitness and selection associated with gene-environment inter-
action. The fmdmg of a very different geographical distribution for the
prothrombin variant renders these explanations less likely. Probably,
founder effects have played a much more important role. Interestingly,
both factor V Leiden and prothrombin 2021 OA appear common in the
Middle-East [14] and m Cyprus [9,15].
We have combined data from centres that used different cnteria to
recruit individuals, which raises questions about the comparability.
Most centres excluded individuals with a history of thrombosis, or
recruited blood donors and volunteers amongst whom such a history is
unlikely. Although this would lead to lower estimates than obtained
from a theoretically ideal study group of consecutive newborns, this
difference is immatenal. Selection bias leading to overestimation
would have occurred if for some reason individuals with thrombotic
disease had been preferentially included. This bias did not occur, since
the medical controls either comprised patients with disorders that
are not associated with prothrombotic mutations (rheumatoid arthritis,
orthopedic trauma), or, individuals without a history of thrombosis.
Factor V Leiden is extremely rare among non-Caucasians, which is
in accordance with the estimated age of the mutation of 21,000 to
34,000 years [16], ie, occurrmg after the divergence of Africans from
non-Afncans and Caucasians from Asians [16]. Although the number
of non-Caucasians in our collaborative study was relatively small, we
found only 0.67 percent prevalence of carriers among individuals with
an African background, and no camers among Native Americans.
In another recent report, no carriers were found among 40 Somalians
[9]. These findings suggests a low pievalence of prothrombin 20210A
among Africans and Asians, äs has been reported also for factor V
Leiden [15,16].
We conclude that prothrombin 2021 OA is a common prothrombotic
genetic variant, that has a pievalence of carriership between one and
four percent. There are geographic differences m this prevalence, with
a higher frequency m southern than m northern Europe. In areas with a
high prevalence this variant may contribute significantly to the occur-
rence of thrombotic disease in the population.
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